Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 6/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HBB | P68871 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9934185 | 0.85 | ABL1 (0.40) | KMOKDM4ENTRK1LMNAMAPK1 | |
| SCHEMBL4508432 | 0.77 | KDM4E (0.50) | KMOHSD17B10KDM4EMAPTTDP1 | |
| SCHEMBL23055223 | 0.75 | KMO (0.50) | KMOHSD17B10KDM4EMAPTTDP1 | |
| SCHEMBL2244617 | 0.75 | XDH (0.46) | HSD17B10MAPTEGFRLMNAHPGD | |
| SCHEMBL30252102 | 0.74 | HCAR2 (0.33) | HSD17B10EGFRLMNACYP1A2CYP2C9 | |
| SCHEMBL17261540 | 0.74 | HCAR2 (0.33) | HSD17B10EGFRLMNACYP1A2CYP2C9 | |
| SCHEMBL9983135 | 0.72 | NPC1 (0.41) | HSD17B10KDM4ECYP1A2CYP2C9CYP3A4 | |
| SCHEMBL31162924 | 0.72 | NPC1 (0.41) | HSD17B10KDM4ECYP1A2CYP2C9CYP3A4 | |
| SCHEMBL24784034 | 0.72 | NOTUM (0.52) | NTRK1EGFRMEN1KMT2A | |
| SCHEMBL30135342 | 0.72 | RECQL (0.54) | HSD17B10MAPTLMNAHPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2708538-B1 | Process for preparing fused pyrimidine-dione derivatives, useful as as TRPA1 modulators | GLENMARK PHARMACEUTICALS SA (CH) | 2015-08-12 | — | — | EP | disclosed |
| US-9000159-B2 | Fused pyrimidine-dione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-04-07 | — | — | US | disclosed |
| US-20140128603-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2014-05-08 | — | — | US | disclosed |
| EP-2708538-A1 | Process for preparing fused pyrimidine-dione derivatives, useful as as TRPA1 modulators | Glenmark Pharmaceuticals S.A. (CH) | 2014-03-19 | — | — | EP | disclosed |
| EP-2411393-B1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-8623880-B2 | Fused pyrimidine-dione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2014-01-07 | — | — | US | disclosed |
| US-20120041004-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-02-16 | — | — | US | disclosed |
| EP-2411393-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010109287-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128603-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | KMO 1531/4885HSD17B10 3078/4885KDM4E 4718/4885 |
| US-20120041004-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS | TRPA1, TRPV1, TRPC3 | KMO 886/4885HSD17B10 3549/4885KDM4E 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.